

Charité – Universitätsmedizin Berlin

Campus Benjamin Franklin

Medizinische Klinik III (Hämatologie, Onkologie und Transfusionsmedizin)

Geschäftsführender Direktor: Prof. Dr. E. Thiel

Regulation of Wilms Tumor Gene 1 (WT1) expression in human neoplasia

Inaugural-Dissertation

Zur Erlangung der Medizinischen Doktorwürde

An Der Charité - Universitätsmedizin Berlin

Campus Benjamin Franklin

Vorgelegt von Emilian Snarski

Aus Elk, Polen

Referent: Prof. Dr. med. U. Keilholz

Korreferent: Prof. Dr. med. Dr. h. c. G. Henze

Gedruckt mit Genehmigung der Charité – Universitätsmedizin Berlin
Campus Benjamin Franklin

Promoviert am: 02.12.2005

	Page	
1	Summary	5
2	Introduction	7
2.1	WT1 Wilms' Tumor Gene 1	7
2.1.1	Characteristics of WT1 gene product	7
2.1.2	Regulation of WT1 Expression	7
2.2	PAX2	8
2.3	PAX8	9
2.4	GATA1	9
2.5	WT1 expression in leukemia	10
2.6	WT1 expression in solid tumors	11
2.7	Prospects of immune therapy against WT1	11
2.8	WT1 expression and regulatory sequence methylation	12
3	Aims	14
4	Materials	15
4.1	Laboratory apparatus	15
4.2	Kits	15
4.3	Enzymes	16
4.4	Reagents	16
4.5	Other materials	17
4.6	Cell culture mediums	17
4.7	Cell lines	18
4.8	Blood and tissue samples	19
4.9	QRT-PCR Primers and Hybridization Probes	19
4.10	PCR Primers	19
4.11	Matrix ssDNA Oligos	20
5	Methods	21
5.1	RNA isolation	21
5.2	DNA isolation	21
5.3	siRNA design	22
5.4	siRNA synthesis protocol	24
5.5	siRNA labeling protocol	27
5.6	Nucleic acid quantification	27
5.7	Gelelectrophoretic analysis of nucleic acids	27
5.7.1	PCR and qRT-PCR products	27
5.7.2	siRNA	28
5.8	cDNA synthesis	28
5.9	siRNA transfection protocol	29
5.10	Light Cycler reaction conditions	30
5.11	PCR reaction conditions	31
5.12	Restriction Protocols	31

5.13	Methylation protocol	32
5.14	Statistical analysis	33
6	Results	34
6.1	Coexpression of WT1 and its regulators in carcinomas	34
6.1.1	WT1 and its putative regulators expression pattern in carcinoma cell lines	34
6.1.2	WT1 and its regulators expression patterns in patients samples	34
6.1.3	Correlation between expression level of <i>WT1</i> and of its putative regulators.	35
6.2	RNA interference	39
6.2.1	Transfection with fluorescent labeled siRNA allows rapid optimization of transfection protocol	39
6.2.2	Kinetic experiments	40
6.2.3	Factors influencing efficiency of transfection	41
6.2.4	SiRNAs synthesized with Silencer siRNA Construction Kit are able to efficiently silence mRNA expression	42
6.2.5	Toxicity of different commercially available transfection agents	44
6.2.6.1	WT1 RNA interference in K562	45
6.2.6.2	WT1 RNA interference in HEL	48
6.2.6.3	GATA1 RNA interference in K562	50
6.2.6.4	GATA1 RNA interference in HEL	53
6.2.6.5	PAX8 RNA interference in HBL 100	54
6.2.6.6	PAX2 RNA interference in HL60	56
6.3	Mutation analysis of promoter regions of studied genes in patients with AML	57
6.3.1	WT1 promoter	57
6.3.2	WT1 enhancer	58
6.3.3	GATA1 promoter	60
6.3.4	PAX2 promoter	61
6.3.5	PAX8 promoter	62
6.4	Quantitative methylation analysis	63
6.5	Enhancer methylation status and gene expression levels	66
7	Discussion	69
7.1	Expression of WT1 and its regulators in human carcinomas	72
7.2	RNA interference	72
7.2.1	Optimization of cells transfection efficiency	72
7.2.2	RNAi of the housekeeping genes	74
7.2.3	RNAi of the WT1 and its regulators	75
7.3	Sequence analysis of the promoter regions of WT1 gene and its regulators in AML patients	79

7.4	Methylation analysis	80
8	Abbreviations	83
9	Acknowledgements	85
10	References	86
11	Curriculum vitae	96